deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03162055

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)

A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)

Sponsor: AstraZeneca

Conditions Chronic Obstructive Pulmonary Disease COPD
Interventions Glycopyrronium/Formoterol Fumarate umeclidinium/vilanterol
Updated 13 times since 2017 Last updated: Apr 30, 2019 Started: May 25, 2017 Primary completion: May 4, 2018 Completion: May 4, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Obstructive Pulmonary Disease COPD, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 13 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jun 2019 · 11 months · monthly snapshot~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 8 earlier versions

  1. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jul 2018 — Jun 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  7. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  8. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • CISCRP
  • Cognizant Technology Solution
  • Corporate Translations Inc
  • Parexel International Ltd
  • QuintilesIMS Limited
  • eResearchTechnology
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Balassagyarmat, Hungary , Barnaul, Russia , Besançon, France , Brest, France , Budapest, Hungary , Burlington, Canada , Chelyabinsk, Russia , Chernivtsi, Ukraine , Debrecen, Hungary , Dublin, United States and 74 more locations